Does Zetia (ezetimibe) cause side effects?
Zetia (ezetimibe) is a lipid-lowering compound used to treat high cholesterol. Common side effects of ezetimibe include diarrhea, abdominal pain, back pain, joint pain, muscle aches, and sinus infection (sinusitis).
Serious side effects of ezetimibe include hypersensitivity reactions (including angioedema - swelling of the skin and underlying tissues of the head and neck - that can be life-threatening), skin rash, nausea, pancreatitis, muscle damage (myopathy or rhabdomyolysis), and hepatitis.
Drug interactions of ezetimibe include cholestyramine, colestipol, colesevelam, and cyclosporine.
There are no adequate studies of ezetimibe in pregnant women. The benefits of using ezetimibe during pregnancy must be weighed against potential but unknown risks. There are no adequate studies of ezetimibe in breastfeeding women. The benefits of using ezetimibe in nursing women must be weighed against potential but unknown risks.
What are the important side effects of Zetia (ezetimibe)?
The most common side effects of Zetia are:
- diarrhea,
- abdominal pain,
- back pain,
- joint pain,
- muscle aches, and
- sinusitis.
Hypersensitivity reactions, including angioedema (swelling of the skin and underlying tissues of the head and neck that can be life-threatening) and skin rash rarely occur.
Other important side effects include:
Zetia (ezetimibe) side effects list for healthcare professionals
The following serious adverse reactions are discussed in greater detail in other sections of the label:
- Liver enzyme abnormalities
- Rhabdomyolysis and myopathy
Monotherapy Studies
In the Zetia controlled clinical trials database (placebo-controlled) of 2396 patients with a median treatment duration of 12 weeks (range 0 to 39 weeks), 3.3% of patients on Zetia and 2.9% of patients on placebo discontinued due to adverse reactions. The most common adverse reactions in the group of patients treated with Zetia that led to treatment discontinuation and occurred at a rate greater than placebo were:
- Arthralgia (0.3%)
- Dizziness (0.2%)
- Gamma-glutamyltransferase increased (0.2%)
The most commonly reported adverse reactions (incidence ≥2% and greater than placebo) in the Zetia monotherapy controlled clinical trial database of 2396 patients were: upper respiratory tract infection (4.3%), diarrhea (4.1%), arthralgia (3.0%), sinusitis (2.8%), and pain in extremity (2.7%).
Statin Coadministration Studies
In the Zetia + statin controlled clinical trials database of 11,308 patients with a median treatment duration of 8 weeks (range 0 to 112 weeks), 4.0% of patients on Zetia + statin and 3.3% of patients on statin alone discontinued due to adverse reactions. The most common adverse reactions in the group of patients treated with Zetia + statin that led to treatment discontinuation and occurred at a rate greater than statin alone were:
- Alanine aminotransferase increased (0.6%)
- Myalgia (0.5%)
- Fatigue, aspartate aminotransferase increased, headache, and pain in extremity (each at 0.2%)
The most commonly reported adverse reactions (incidence ≥2% and greater than statin alone) in the Zetia + statin controlled clinical trial database of 11,308 patients were: nasopharyngitis (3.7%), myalgia (3.2%), upper respiratory tract infection (2.9%), arthralgia (2.6%) and diarrhea (2.5%).
Clinical Trials Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.
Monotherapy
In 10 double-blind, placebo-controlled clinical trials, 2396 patients with primary hyperlipidemia (age range 9-86 years, 50% women, 90% Caucasians, 5% Blacks, 3% Hispanics, 2% Asians) and elevated LDL-C were treated with Zetia 10 mg/day for a median treatment duration of 12 weeks (range 0 to 39 weeks).
Adverse reactions reported in ≥2% of patients treated with Zetia and at an incidence greater than placebo in placebo-controlled studies of Zetia, regardless of causality assessment, are shown in Table 1.
TABLE 1: Clinical Adverse Reactions Occurring in
≥2% of Patients Treated with Zetia and at an Incidence Greater than
Placebo, Regardless of Causality
Body System/Organ Class Adverse Reaction |
Zetia 10 mg (%) n = 2396 |
Placebo (%) n = 1159 |
Gastrointestinal disorders | ||
Diarrhea | 4.1 | 3.7 |
General disorders and administration site conditions | ||
Fatigue | 2.4 | 1.5 |
Infections and infestations | ||
Influenza | 2.0 | 1.5 |
Sinusitis | 2.8 | 2.2 |
Upper respiratory tract infection | 4.3 | 2.5 |
Musculoskeletal and connective tissue disorders | ||
Arthralgia | 3.0 | 2.2 |
Pain in extremity | 2.7 | 2.5 |
The frequency of less common adverse reactions was comparable between Zetia and placebo.
Combination with a Statin
In 28 double-blind, controlled (placebo or active-controlled) clinical trials, 11,308 patients with primary hyperlipidemia (age range 10-93 years, 48% women, 85% Caucasians, 7% Blacks, 4% Hispanics, 3% Asians) and elevated LDL-C were treated with Zetia 10 mg/day concurrently with or added to on-going statin therapy for a median treatment duration of 8 weeks (range 0 to 112 weeks).
The incidence of consecutive increased transaminases (≥3 × ULN) was higher in patients receiving Zetia administered with statins (1.3%) than in patients treated with statins alone (0.4%).
Clinical adverse reactions reported in ≥2% of patients treated with Zetia + statin and at an incidence greater than statin, regardless of causality assessment, are shown in Table 2.
TABLE 2: Clinical Adverse Reactions Occurring in
≥2% of Patients Treated with Zetia Coadministered with a Statin and at an
Incidence Greater than Statin, Regardless of Causality
Body System/Organ Class Adverse Reaction | All Statins* (%) n=9361 |
Zetia + All Statins* (%) n = 11,308 |
Gastrointestinal disorders | ||
Diarrhea | 2.2 | 2.5 |
General disorders and administration site conditions | ||
Fatigue | 1.6 | 2.0 |
Infections and infestations | ||
Influenza | 2.1 | 2.2 |
Nasopharyngitis | 3.3 | 3.7 |
Upper respiratory tract infection | 2.8 | 2.9 |
Musculoskeletal and connective tissue disorders | ||
Arthralgia | 2.4 | 2.6 |
Back pain | 2.3 | 2.4 |
Myalgia | 2.7 | 3.2 |
Pain in extremity | 1.9 | 2.1 |
* All Statins = all doses of all statins |
Combination with Fenofibrate
This clinical study involving 625 patients with mixed dyslipidemia (age range 20-76 years, 44% women, 79% Caucasians, 0.1% Blacks, 11% Hispanics, 5% Asians) treated for up to 12 weeks and 576 patients treated for up to an additional 48 weeks evaluated coadministration of Zetia and fenofibrate. This study was not designed to compare treatment groups for infrequent events. Incidence rates (95% CI) for clinically important elevations (≥3 — ULN, consecutive) in hepatic transaminase levels were 4.5% (1.9, 8.8) and 2.7% (1.2, 5.4) for fenofibrate monotherapy (n=188) and Zetia coadministered with fenofibrate (n=183), respectively, adjusted for treatment exposure. Corresponding incidence rates for cholecystectomy were 0.6% (95% CI: 0.0%, 3.1%) and 1.7% (95% CI: 0.6%, 4.0%) for fenofibrate monotherapy and Zetia coadministered with fenofibrate, respectively [see DRUG INTERACTIONS]. The numbers of patients exposed to coadministration therapy as well as fenofibrate and ezetimibe monotherapy were inadequate to assess gallbladder disease risk. There were no CPK elevations > 10 — ULN in any of the treatment groups.
Post-Marketing Experience
Because the reactions below are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The following additional adverse reactions have been identified during post-approval use of Zetia:
Hypersensitivity reactions, including anaphylaxis, angioedema, rash, and urticaria; erythema multiforme; arthralgia; myalgia; elevated creatine phosphokinase; myopathy/rhabdomyolysis; elevations in liver transaminases; hepatitis; abdominal pain; thrombocytopenia; pancreatitis; nausea; dizziness; paresthesia; depression; headache; cholelithiasis; cholecystitis.
What drugs interact with Zetia (ezetimibe)?
Cyclosporine
Caution should be exercised when using Zetia and cyclosporine concomitantly due to increased exposure to both ezetimibe and cyclosporine. Cyclosporine concentrations should be monitored in patients receiving Zetia and cyclosporine.
The degree of increase in ezetimibe exposure may be greater in patients with severe renal insufficiency. In patients treated with cyclosporine, the potential effects of the increased exposure to ezetimibe from concomitant use should be carefully weighed against the benefits of alterations in lipid levels provided by ezetimibe.
Fibrates
The efficacy and safety of coadministration of ezetimibe with fibrates other than fenofibrate have not been studied.
Fibrates may increase cholesterol excretion into the bile, leading to cholelithiasis. In a preclinical study in dogs, ezetimibe increased cholesterol in the gallbladder bile. Coadministration of Zetia with fibrates other than fenofibrate is not recommended until use in patients is adequately studied.
Fenofibrate
If cholelithiasis is suspected in a patient receiving Zetia and fenofibrate, gallbladder studies are indicated and alternative lipid-lowering therapy should be considered.
Cholestyramine
Concomitant cholestyramine administration decreased the mean area under the curve (AUC) of total ezetimibe approximately 55%. The incremental LDL-C reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction.
Coumarin Anticoagulants
If ezetimibe is added to warfarin, a coumarin anticoagulant, the International Normalized Ratio (INR) should be appropriately monitored.
Summary
Zetia (ezetimibe) is a lipid-lowering compound used to treat high cholesterol. Common side effects of ezetimibe include diarrhea, abdominal pain, back pain, joint pain, muscle aches, and sinus infection (sinusitis).
Multimedia: Slideshows, Images & Quizzes
-
Cholesterol Levels: What's Normal and How to Lower High Cholesterol
What do cholesterol numbers mean? LDL, HDL, good, bad, and triglycerides - Get the facts on cholesterol, blood testing,...
-
How to Lower Your Cholesterol & Save Your Heart
Need to lower your cholesterol levels? Use these smart diet tips to quickly and easily lower your blood cholesterol levels....
-
Cholesterol Drugs: What to Expect With Heart Medication
When diet and exercise aren't enough, should you turn to drugs? Learn cholesterol basics, drug classes, and available drugs along...
-
Cholesterol: High Triglyceride Foods to Avoid
High triglycerides increase the risk of heart disease. Lower triglyceride levels and reduce cholesterol by eating foods that...
-
High Cholesterol (Hyperlipidemia) Quiz: Test Your Medical IQ
High cholesterol can be a dangerous condition. Take the Cholesterol Quiz to understand what high cholesterol means in terms of...
-
Picture of Cholesterol
Cholesterol carried in particles of low density (LDL cholesterol) is referred to as the "bad" cholesterol because elevated levels...
Related Disease Conditions
-
Cholesterol Management
High cholesterol and triglyceride levels increase the risk of cardiovascular disease. Getting your cholesterol and triglyceride levels in an optimal range will help protect your heart and blood vessels. Cholesterol management may include lifestyle interventions (diet and exercise) as well as medications to get your total cholesterol, LDL, HDL, and triglycerides in an optimal range.
-
Lower Cholesterol Levels with Diet and Medications
High-density lipoprotein (HDL) cholesterol is considered "good" cholesterol because it actually works to keep the LDL or "bad" cholesterol from building up in your arteries. Foods like extra lean meats, skim milk, and vegetable-based "butter-like" substitutes may help decrease LDL levels in the bloodstream.
-
HDL vs. LDL Cholesterol (Good and Bad)
HDL (high-density lipoprotein), or the "good" cholesterol, and LDL (low-density lipoprotein), or the "bad" cholesterol, are lipoproteins that carry cholesterol through the veins and arteries of the body. HDL and LDL combined, is your "total" blood cholesterol. The difference between the two are that high levels of the "good," or HDL cholesterol, may protect against narrowing of the blood vessels in the body, which protects you against heart attack, stroke, and other cardiovascular diseases. But high levels of LDL, or the "bad" cholesterol, may worsen the narrowing of the blood vessels in the body, which puts you at a greater risk of stroke, heart attack, and cardiovascular diseases, some of which are life threatening.Triglycerides are found in body fat and from the fats you eat.
Treatment & Diagnosis
- High Cholesterol (Hyperlipidemia) FAQs
- Statins - - Doing More Than Lowering Your Cholesterol?
- Cholesterol: Questions To Ask Your Doctor
- Cholesterol: The Truth About Cholesterol
- Cholesterol: HDL cholesterol ratio
- Cholesterol - Mr. D.T.'s Story of Hope
- Cholesterol Guidelines for Adults (2001)
- Cholesterol Guidelines
- Heart Attack Prevention From a Doctor's Perspective
- What Should Cholesterol Levels Be After Heart Attack?
- Can Menopause Cause High Cholesterol?
- What are Cholesterol-Lowering Statins?
- Do Bile Acid Resins Lower Cholesterol?
- Can Fibrate Drugs Lower Cholesterol?
- How Do I Lower My Cholesterol (Triglycerides)
- Does Hypothyroidism Cause High Cholesterol?
- Does Exercise Lower Cholesterol?
- What Foods Lower Cholesterol?
- Does Stress Cause High Cholesterol?
- Cholesterol Treatment
- Cholesterol, The Basics Of Prevention
Medications & Supplements

Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.